GSK Plc: An Increased Adoption of Depemokimab in Asthma Treatment & Other Major Drivers! 

GlaxoSmithKline (GSK) recently announced its Q1 2025 financial results. The company reported steady progress with its sales increasing by 4% and core operating profit growing by 5%. Core earnings per share also rose by 5% to 44.9p. Driving this growth was GSK’s Specialty Medicines unit, which saw a remarkable 17% sales increase, with strong performances in therapies related to respiratory, immunology, inflammation, oncology, and HIV. However, GSK faced a 6% decline in vaccine sales, primarily due to anticipated headwinds in this segment and static sales in general medicines.